How to use sound to relieve tinnitus without wasting your money.

What would you be willing to pay to get rid of your tinnitus?

Learn about biobanks and tinnitus data.

What is it really like living with tinnitus? Hazel speaks with Steve and Sean.

Can psychedelics 'detach' the brain from tinnitus?

Will Otonomy’s tinnitus drug also work for chronic cases?

Can we measure the intangible nature of tinnitus?

Seeing phantom visions, hearing phantom sounds.

This episode will give you a deeper understanding of the different models that explain the brain mechanisms underlying tinnitus. Dr Will Sedley outlines his own theory, based on predictive processing. We also cover issues like how to develop an objective marker of tinnitus and the thorny topic of whether tinnitus subtypes really exist or not.

This is your chance to learn all about the hearing regeneration treatment FX-322 being developed by Frequency Therapeutics. We spoke with Carl LeBel about the promising results of their Phase 1 trial, the potential benefits for tinnitus, why speech intelligibility should be the primary measure of hearing, and when the drug might reach the market.

A drug to quieten your tinnitus, that’s what Thanos Tzounopoulos, PhD, is working on. The drug targets potassium ion channels in the brain. These channels – or so the theory goes – are compromised in tinnitus patients, thus triggering the neural hyperactivity perceived as tinnitus. In spite of trials and tribulations in getting the drug ready for clinical trials, Thanos is optimistic about his chances for success.

In this special compilation episode, you’ll hear from four people with tinnitus, as well as a researcher and an audiologist, about tinnitus experiences during the Coronavirus crisis. How has the stress of the crisis impacted people’s tinnitus? Can the Coronavirus cause tinnitus to aggravate? What kind of support is available for people struggling during this time?

Tinnitus Talk spoke with the Hough Ear Institute, a non-profit research organization that focusses on restoring hearing. They are working on two hearing regeneration treatments that could very well have benefits for tinnitus sufferers. In this episode, we spoke with Dr. Richard Kopke and Justin DeMoss. They explain the mechanisms behind their treatments and how hearing restoration can be achieved. They take us through the different phases of research and development required to get new drugs to market, and some of the challenges faced along the way. Of course, we also touch on the topic of whether restoring hearing could cure tinnitus. The episode includes an announcement about an exciting new partnership with pharmaceutical company Oblato to take Hough’s hearing loss pill through the next phases of clinical trial and assess its potential for tinnitus.

Tinnitus Talk spoke with Bryan Pollard, the president of Hyperacusis Research Limited, based in Boston. Bryan himself suffers from hyperacusis, which he believes is due to sound exposure from a loud woodchipper several years ago. In this episode, Bryan talks about his personal experience with hyperacusis, and how this drove him to start Hyperacusis Research to raise funds for scientific research. We spoke about the concept of pain hyperacusis and how it only recently became recognized due to the scientific breakthrough proving that the cochlea has pain receptors. Bryan also gives advice to hyperacusis patients regarding treatment options. And of course, we spoke about the most exciting new research developments.

It’s been the talk of the town on the Tinnitus Talk forum for the past few months: the launch of Neuromod’s Lenire treatment for tinnitus. We got a chance to sit down with their CEO Dr. Ross O’Neill and ask him everything (well, nearly) you want to know about this device. It’s an extra-long episode, because so many questions were raised on our forum about Lenire – the thread has been viewed over half a million times – that we felt we needed to do our best to gather as many answers as possible. In the episode, Hazel and Ross talk about the basic principles of the treatment, its effectiveness, and risks. We also covered clinical trial results and go in-depth on what the treatment actually looks like. We clarify whom Lenire is suitable for, and Ross makes some projections about future roll-out of the device.

What is the current state of evidence in favour or against tinnitus treatments on the market? Which treatments have been thoroughly tested and which require more testing? What should doctors and patients learn from this? And how should this inform new tinnitus research? These are all questions answered in this episode! Tinnitus Talk spoke with Rilana Cima and Derek Hoare, two of the co-authors of the European Clinical Practice Guidelines for Tinnitus, which were published earlier this year. Clinical Guidelines are recommendations for healthcare professionals on how to diagnose and treat a medical condition, based on currently available evidence. The episode makes clear that the vast majority of treatments currently on the market have not been sufficiently studied to tell one way or the other how effective and safe they are. There is a dire lack of thorough clinical trial data available, which severely hinders clinical management of tinnitus. Doctors are often not aware of different treatment options, and patients have to find their own way through the system. If you are currently seeking medical treatment for tinnitus, make sure you are aware of any relevant Clinical Guidelines.